Remove Development Remove Licensing Remove Pharmaceuticals Remove Programming
article thumbnail

Seattle Children’s spins out BrainChild Bio, a startup developing therapies for incurable brain cancers

GeekWire

The startup has an exclusive license to use novel CAR T-cell technology developed by Jensen and his team. “With our clinical trials and our academic programs, we can treat and help dozens or tens of dozens of patients,” Jensen said. Steven Brugger will join BrainChild Bio as CEO.

article thumbnail

Univ. of Wash.-spinout Icosavax raises $100M to fund vaccine development technology

GeekWire

Icosavax creates virus-like particles with technology licensed from the University of Washington’s Institute for Protein Design. The company launched its COVID program in October, supported in part by $10 million from the Bill & Melinda Gates Foundation. Icosavax Photo).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What is NLP? Natural language processing explained

CIO Business Intelligence

They integrate with Slack, Microsoft Messenger, and other chat programs where they read the language you use, then turn on when you type in a trigger phrase. That’s why critics say these programs are always listening; if they weren’t, they’d never know when you need them. NLTK is offered under the Apache 2.0 Amazon Comprehend.

Course 142
article thumbnail

Alpine raises $91M to fuel the Seattle biotech’s clinical trials for lupus and cancer

GeekWire

The funding will fuel Alpine’s program developing ALPN-303, designed to treat lupus and other inflammatory diseases. That payment is part of a licensing deal inked last year with the pharmaceutical giant for clinical testing of another immune-modulating agent, ALPN-101, for lupus. That’s a 4.4%

article thumbnail

Seattle biotech startup AltPep raises $23.1M to tackle Alzheimer’s and related diseases

GeekWire

AltPep is developing tools and treatments for diseases caused by amyloid proteins that are incorrectly folded and create harmful deposits. The UW has licensed the exclusive rights of this intellectual property to the startup. Another Seattle-area biotech startup, Athira Pharma, is also developing treatments for Alzheimer’s.

article thumbnail

Merck’s multi-billion dollar bet on Seattle Genetics sparks hope for breast cancer treatments

GeekWire

based biotechnology company struck a deal with Merck in which the pharmaceutical powerhouse will provide a $600 million upfront payment and make a $1 billion equity investment to continue development of treatments for breast cancer. billion if development milestones are met, and another $1.75

article thumbnail

Impel NeuroPharma, fresh off IPO, gets FDA approval for nasal spray that treats migraines

GeekWire

“When I founded the company, I never really expected to get a product on the market to patients,” said Hoekman, who served as CEO until 2017 and is now chief technology and development officer. It’s been a “big challenge to shift from a device technology-focused company to what is now a pretty integrated pharmaceutical company,” said Hoekman.